Microbiota and Pancreatic Cancer Cachexia

Recruiting now

Conditions studied: Pancreatic Cancer, Microbiota, Cachexia

In brief

This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.

Key facts

Study ID

NCT05606523

Run by

Genton Graf Laurence

People needed

24

Starts

2022-08-01

Expected to finish

2025-04-30

Last updated by the study team

2024-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with pancreatic cancer (n=12)
• ≥18 years and
• Newly diagnosed of pancreatic adenocarcinoma (local or metastatic) and
• Tube feeding or parenteral nutrition ≤ 14 days
• Cachectic pancreatic cancer patients (n=6)
• Cachexia according to the Fearon criteria 1: involuntary weight loss >5% over the last 6 months, or any level of weight loss >2% and a BMI <20 kg/m2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is <17 kg/m2 in men and <15 kg/m2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6)
• Normal nutritional state: weight stability (± 2% of habitual weight) over the last 6 months, no anorexia before the diagnosis (appetite rating on a visual analogue scale of 100mm), no known impaired glucose tolerance.
• Healthy matched subjects (n=12)
• ≥18 years and
• BMI between 18.5 and 30 kg/m2 and
• Absence of chronic or acute disease and
• Matching for gender and age (± 5 years) with an included pancreatic cancer patient

You may not qualify if…

• < 18 years or
• Inability to give consent or
• Insufficient knowledge of project language (French, German) or
• Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion
• Known rheumatologic or immunologic diseases
• Therapeutic antibiotics or immunosuppressive drugs (for instance glucocorticoids, cytostatics, antibodies) in the 30 days preceding the inclusion

Where it is running

• Geneva University Hospitals — Geneva, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.